We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-8.9%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$525M
AUM Growth
-$493M
Cap. Flow
-$400M
Cap. Flow %
-76.25%
Top 10 Hldgs %
41.99%
Holding
85
New
22
Increased
4
Reduced
37
Closed
18

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$18.6M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$11.7M
3
COR icon
Cencora
COR
+$9.87M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$8.59M
5
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$8.4M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$33.8M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$29.5M
3
ACHC icon
Acadia Healthcare
ACHC
+$26.1M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$25.4M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$20.2M

Sector Composition

Rank Sector Weight
1 Healthcare 90.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
26
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$7.62M 1.45%
+94,000
New +$8.4M
CNTA
27
DELISTED
Centessa Pharmaceuticals
CNTA
$7.61M 1.45%
529,000
-636,800
-55% -$10.4M
RVMD icon
28
Revolution Medicines
RVMD
$39.1B
$7.53M 1.44%
213,000
-233,200
-52% -$9.47M
TEVA icon
29
Teva Pharmaceuticals
TEVA
$36.9B
$7.39M 1.41%
+481,000
New +$8.59M
AVTR icon
30
Avantor
AVTR
$8.48B
$7.34M 1.4%
453,000
-494,000
-52% -$9.36M
IDYA icon
31
IDEAYA Biosciences
IDYA
$3.48B
$7.29M 1.39%
445,000
-681,700
-61% -$14.5M
DOCS icon
32
Doximity
DOCS
$3.85B
$7.11M 1.35%
+122,500
New +$7.74M
JANX icon
33
Janux Therapeutics
JANX
$915M
$6.97M 1.33%
258,000
-483,900
-65% -$18.2M
HQY icon
34
HealthEquity
HQY
$8.46B
$6.89M 1.31%
+78,000
New +$8M
BPMC
35
DELISTED
Blueprint Medicines
BPMC
$6.06M 1.16%
68,500
-108,100
-61% -$10.5M
ARVN icon
36
CALL
Arvinas
ARVN
$529M
$5.26M 1%
750,000
+50,000
+7% +$784K
UTHR icon
37
United Therapeutics
UTHR
$26.1B
$5.18M 0.99%
+16,800
New +$5.76M
PHAT icon
38
Phathom Pharmaceuticals
PHAT
$930M
$5.02M 0.96%
800,000
-590,100
-42% -$3.58M
SNDX icon
39
CALL
Syndax Pharmaceuticals
SNDX
$1.74B
$4.91M 0.94%
+400,000
New +$5.64M
IMUX icon
40
Immunic
IMUX
$182M
$4.86M 0.93%
445,441
-351,199
-44% -$3.79M
BRKR icon
41
Bruker
BRKR
$9.58B
$4.8M 0.91%
115,000
+38,700
+51% +$2.01M
CATX icon
42
Perspective Therapeutics
CATX
$327M
$4.68M 0.89%
2,197,270
-497,330
-18% -$1.49M
CNTX icon
43
Context Therapeutics
CNTX
$54.3M
$4.58M 0.87%
7,477,200
– –
ORKA
44
Oruka Therapeutics
ORKA
$5.46B
$3.61M 0.69%
352,124
– –
QURE icon
45
uniQure
QURE
$2.52B
$3.56M 0.68%
336,200
+114,200
+51% +$1.6M
BHVN icon
46
Biohaven
BHVN
$2.07B
$3.49M 0.66%
145,000
-77,900
-35% -$2.75M
ARVN icon
47
Arvinas
ARVN
$529M
$2.9M 0.55%
413,162
-944,838
-70% -$14.8M
ACAD icon
48
Acadia Pharmaceuticals
ACAD
$4.45B
$2.81M 0.54%
+169,000
New +$3.07M
RPRX icon
49
Royalty Pharma
RPRX
$26.6B
$2.71M 0.52%
+87,000
New +$2.76M
BBIO icon
50
BridgeBio Pharma
BBIO
$16.8B
$2.59M 0.49%
+75,000
New +$2.53M
1
2
3 4

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q1 2025 Portfolio in Review

As of Q1 2025, Avidity Partners Management held 85 positions worth $525M, down 48% from $1.02B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Avidity Partners Management withdrew a net $400M in Q1 2025, closing 18 positions and reducing 37 holdings. Its most notable exit was Intuitive Surgical, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 99% a quarter earlier.

Against the trend, Avidity Partners Management opened a new position in Beam Therapeutics worth $13.9M.

  • Avidity Partners Management's largest Q1 2025 buy was Beam Therapeutics: 709,517 shares worth $13.9M.
  • Avidity Partners Management added most to Regeneron Pharmaceuticals in Q1 2025, an estimated $11.7M increase.
  • Avidity Partners Management's biggest Q1 2025 reduction was Mirum Pharmaceuticals, cutting an estimated $29.5M.
  • Avidity Partners Management fully exited Intuitive Surgical in Q1 2025, selling an estimated $33.8M.
  • Avidity Partners Management's ten largest holdings make up 42% of its $525M portfolio in Q1 2025.
  • Avidity Partners Management opened 22 new positions and closed 18 in Q1 2025.
  • Avidity Partners Management's portfolio value fell 48% quarter-over-quarter to $525M.

Based on Avidity Partners Management's 13F filing for Q1 2025, filed 15 May 2025.